What is XNCR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.59B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for XNCR?

P/E (TTM) is n/a and 52-week range is $10.38 to $30.61 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s XNCR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for XNCR?

The company profile lists revenue (TTM) near $103M, net income (TTM) near $-15.96B, EPS (TTM) near $-2.17 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Xencor Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Pasadena, California, US, 74.1M shares outstanding, ISIN US98401F1057 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Xencor Inc

$XNCR

Health Care · Biotechnology

IR Run Scenarios

$24.63

+0.53%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 260 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Employees

260

Website

xencor.com/

IPO

2013-12-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)